GSK.L vs. LYP6.DE

Last updated Jun 9, 2026

GSK.L (GlaxoSmithKline plc) is a stock, while LYP6.DE (Amundi Core STOXX Europe 600 (DR) UCITS ETF Acc) is Europe Equities fund tracking the STOXX® Europe 600. Over the past 5 years, GSK.L returned 6.18%/yr vs 9.90%/yr for LYP6.DE. At a 0.39 correlation, their price movements are largely independent.

Performance

GSK.L vs. LYP6.DE - Performance Comparison

The chart below illustrates the hypothetical performance of a £10,000 investment in GlaxoSmithKline plc (GSK.L) and Amundi Core STOXX Europe 600 (DR) UCITS ETF Acc (LYP6.DE). The values are adjusted to include any dividend payments, if applicable.

Different Trading Currencies

GSK.L is traded in GBp, while LYP6.DE is traded in EUR. To make them comparable, the LYP6.DE values have been converted to GBp using the latest available exchange rates.

Returns By Period

The year-to-date returns for both stocks are quite close, with GSK.L having a 6.65% return and LYP6.DE slightly lower at 6.58%.

GSK.L

• 1D: -1.29%
• 1M: 4.74%
• YTD: 6.65%
• 6M: 6.89%
• 1Y: 31.21%
• 3Y*: 16.07%
• 5Y*: 6.18%
• 10Y*: 5.50%

LYP6.DE

• 1D: 0.65%
• 1M: 2.61%
• YTD: 6.58%
• 6M: 9.05%
• 1Y: 19.08%
• 3Y*: 14.13%
• 5Y*: 9.90%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

GSK.L vs. LYP6.DE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
GSK.L GlaxoSmithKline plc	6.65%	41.46%	-3.51%	4.94%	-25.94%	26.66%	-20.76%	25.32%	19.02%	-7.64%
LYP6.DE Amundi Core STOXX Europe 600 (DR) UCITS ETF Acc	6.58%	27.11%	3.53%	13.65%	-5.50%	16.00%	3.83%	21.90%	-10.03%	2.65%

Correlation

The correlation between GSK.L and LYP6.DE is 0.32, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.32
Correlation (3Y) Calculated over the trailing 3-year period	0.31
Correlation (5Y) Calculated over the trailing 5-year period	0.31
Correlation (All Time) Calculated using the full available price history since Sep 20, 2017	0.39

Return for Risk

GSK.L vs. LYP6.DE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GSK.L

GSK.L Risk / Return Rank: 74
GSK.L Sharpe Ratio Rank: 78
GSK.L Sortino Ratio Rank: 76
GSK.L Omega Ratio Rank: 73
GSK.L Calmar Ratio Rank: 72
GSK.L Martin Ratio Rank: 73

LYP6.DE

LYP6.DE Risk / Return Rank: 38
LYP6.DE Sharpe Ratio Rank: 36
LYP6.DE Sortino Ratio Rank: 37
LYP6.DE Omega Ratio Rank: 37
LYP6.DE Calmar Ratio Rank: 36
LYP6.DE Martin Ratio Rank: 42

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GSK.L vs. LYP6.DE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK.L) and Amundi Core STOXX Europe 600 (DR) UCITS ETF Acc (LYP6.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	GSK.L	LYP6.DE	Difference
Sharpe ratio: Return per unit of total volatility	1.25	1.56	-0.32
Sortino ratio: Return per unit of downside risk	1.97	2.24	-0.27
Omega ratio: Gain probability vs. loss probability	1.24	1.29	-0.05
Calmar ratio: Return relative to maximum drawdown	1.69	1.88	-0.18
Martin ratio: Return relative to average drawdown	4.14	6.92	-2.79
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

GSK.L vs. LYP6.DE - Sharpe Ratio Comparison

The current GSK.L Sharpe Ratio is 1.25, which is comparable to the LYP6.DE Sharpe Ratio of 1.56. The chart below compares the historical Sharpe Ratios of GSK.L and LYP6.DE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	GSK.L	LYP6.DE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.25	1.56	-0.32
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.26	0.69	-0.42
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.25	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.24	0.55	-0.31

Drawdowns

GSK.L vs. LYP6.DE - Drawdown Comparison

The maximum GSK.L drawdown since its inception was -42.39%, which is greater than LYP6.DE's maximum drawdown of -27.65%. Use the drawdown chart below to compare losses from any high point for GSK.L and LYP6.DE.

Drawdown Indicators

	GSK.L	LYP6.DE	Difference
Max Drawdown Largest peak-to-trough decline	-42.39%	-27.65%	-14.74%
Max Drawdown (1Y) Largest decline over 1 year	-18.35%	-10.41%	-7.94%
Max Drawdown (3Y) Largest decline over 3 years	-27.42%	-13.78%	-13.64%
Max Drawdown (5Y) Largest decline over 5 years	-42.39%	-16.91%	-25.48%
Max Drawdown (10Y) Largest decline over 10 years	-42.39%	—	—
Current Drawdown Current decline from peak	-14.20%	-1.31%	-12.89%
Average Drawdown Average peak-to-trough decline	-12.77%	-4.24%	-8.53%
Ulcer Index Depth and duration of drawdowns from previous peaks	7.53%	2.83%	+4.70%

Volatility

GSK.L vs. LYP6.DE - Volatility Comparison

GlaxoSmithKline plc (GSK.L) has a higher volatility of 6.21% compared to Amundi Core STOXX Europe 600 (DR) UCITS ETF Acc (LYP6.DE) at 4.10%. This indicates that GSK.L's price experiences larger fluctuations and is considered to be riskier than LYP6.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GSK.L	LYP6.DE	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.21%	4.10%	+2.11%
Volatility (6M) Calculated over the trailing 6-month period	18.11%	10.55%	+7.56%
Volatility (1Y) Calculated over the trailing 1-year period	24.99%	12.51%	+12.48%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	23.68%	14.27%	+9.41%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	22.09%	15.55%	+6.54%

Dividends

GSK.L vs. LYP6.DE - Dividend Comparison

GSK.L's dividend yield for the trailing twelve months is around 3.50%, while LYP6.DE has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
GSK.L GlaxoSmithKline plc	3.50%	3.51%	4.53%	3.84%	5.30%	4.93%	5.90%	4.45%	5.31%	5.99%	4.88%	5.77%
LYP6.DE Amundi Core STOXX Europe 600 (DR) UCITS ETF Acc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions

Can I hold both GSK.L and LYP6.DE in my portfolio?

GSK.L and LYP6.DE have a correlation of 0.32, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.